AMX 0114
Alternative Names: AMX-0114Latest Information Update: 15 Nov 2024
Price :
$50 *
At a glance
- Originator Amylyx Pharmaceuticals
- Class Antisense oligonucleotides
- Mechanism of Action Calpain expression inhibitors; Gene silencing
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Amyotrophic lateral sclerosis; Neurodegenerative disorders
Most Recent Events
- 07 Nov 2024 Amylyx Pharmaceuticals plans a phase I trial for Amyotrophic lateral sclerosis in December 2024 (Intrathecal) (NCT06665165)
- 09 May 2024 Amylyx Pharmaceuticals announces intention to submit an investigational new drug (IND) application to the US FDA for the clinical study of AMX 0114 in amyotrophic lateral sclerosis in the second half of 2024
- 11 Mar 2024 Interim pharmacodynamics data from a preclinical studies in Amyotrophic lateral sclerosis released by Amylyx Pharmaceuticals